BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its $20 million Greenhouse Fund. We invest in therapeutics, devices, diagnostics and platform technologies focused on human health.
Since its first investments in 2003, BioAdvance has become one of the nation’s leading investors providing pre-seed and seed-stage funding. To date we have committed more than $16 million to 26 seed-stage companies and 17 pre-seed companies. Our portfolio companies are working to develop products to treat health problems including Alzheimer’s disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania’s share of tobacco settlement monies.
|Novira Therapeutics||8/12||Series A||$23M||6|
|Relmada Therapeutics||7/12||Series A||$3M||2|
|Ceptaris Therapeutics||6/12||Series D||$10M||6|
|Avid Radiopharmaceuticals||5/09||Series D||$34.5M||8|
|Avid Radiopharmaceuticals||5/07||Series C||$26M||6|
|Avid Radiopharmaceuticals||1/06||Series A||$8.9M||4|